Compare SIFY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIFY | TBPH |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.3M | 824.9M |
| IPO Year | 1999 | 2013 |
| Metric | SIFY | TBPH |
|---|---|---|
| Price | $13.74 | $16.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 51.3K | ★ 473.9K |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $1.04 |
| Revenue Next Year | $14.34 | N/A |
| P/E Ratio | ★ N/A | $8.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.80 | $8.33 |
| 52 Week High | $17.85 | $21.03 |
| Indicator | SIFY | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 60.30 |
| Support Level | $13.44 | $13.41 |
| Resistance Level | $14.62 | $19.04 |
| Average True Range (ATR) | 0.87 | 0.51 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 66.74 | 87.99 |
Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.